Phase 2b Controlled Trial of M72/AS01 Vaccine to Prevent Tuberculosis.

Background: A vaccine to interrupt the transmission of tuberculosis is needed.

Methods: We conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01 tuberculosis vaccine in Kenya, South Africa, and Zambia. Human immunodeficiency virus (HIV)-negative adults 18 to 50 years of age with latent M.